CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07 of this Current Report on Form 8-K is incorporated
herein by reference.
Item5.07 Submission of Matters to a Vote of Security
Holders.
At the Annual Meeting, there were 2,975,218 shares represented to
vote either in person or by proxy, or 69.8% of the outstanding
shares, which represented a quorum. The final results of voting
for each matter submitted to a vote of stockholders at the Annual
Meeting were as follows:
Proposal 1: Election of Directors.
Jeff Himawan, Ph.D. and John P. Richard were elected as Class II
directors for a term of three years. The voting for each director
was as follows:
| For | Withheld | Broker Non-Vote | ||||||||||
|
Jeff Himawan, Ph.D. |
1,134,567 | 116,664 | 1,723,987 | |||||||||
|
John P. Richard |
1,144,225 | 107,006 | 1,723,987 |
Proposal 2: An amendment and restatement of the 2015 Plan
to increase the authorized shares available for issuance under
the 2015 Plan by 950,000 shares, to increase the 162(m) annual
grant limits and to change the non-employee director annual grant
limits to apply to both cash fees and equity awards.
The amendment and restatement of the 2015 Plan was approved based
upon the following votes:
|
For |
Against | Abstain | Broker Non-Vote | |||||||||
|
1,048,360 |
201,243 | 1,628 | 1,723,987 |
Proposal 3: Say on Pay An advisory vote on the approval
of executive compensation.
The Companys executive compensation was approved on a
non-binding, advisory basis based upon the following votes:
|
For |
Against | Abstain | Broker Non-Vote | |||||||||
|
1,070,271 |
132,247 | 48,713 | 1,723,987 |
Proposal 4: Say on Pay Frequency An advisory vote on
whether a stockholder advisory vote on the approval of the
Companys executive compensation should occur every one, two or
three years.
A stockholder advisory vote every one year on the approval of the
Companys executive compensation was approved on a non-binding,
advisory basis based upon the following votes:
|
1 Year |
2Years | 3 Years | Abstain | |||||||||
|
828,609 |
11,051 | 268,496 | 143,075 |
Proposal 5: Ratification of Appointment of Independent
Registered Public Accounting Firm for the Company for the Current
Fiscal Year.
The appointment of EisnerAmper LLP as the Companys independent
registered public accounting firm for fiscal year 2017 was
ratified based upon the following votes:
|
For |
Against | Abstain | Broker Non-Vote | |||||||||
|
2,872,583 |
98,530 | 4,105 | 0 |
Item9.01. Financial Statements and Exhibits.
|
(d)Exhibits |
|
Exhibit No. |
Description of Exhibit |
|
| 10.1* |
Catalyst Biosciences, Inc. (formerly Targacept, Inc.) 2015 Stock Incentive Plan (as Amended and Restated Effective June 15, 2017) (incorporated by reference to Appendix A of the definitive proxy statement for the Annual Meeting filed by the Company on May 18, 2017). |
|
*Management contract or compensatory plan or arrangement. |
About CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO)
Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.